GlassScriptPhysician profile
Kathy M Geraets
NPI 1225472152
$1,242.52
in general payments reported to CMS, 2019-2025
35 companies · $244 in 2025
The $244 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $208 · 2020: $152 · 2021: $143 · 2022: $155 · 2023: $208 · 2024: $133 · 2025: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $584.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $212.74 | 2019-2025 | Evenity, Prolia, Repatha |
| Pfizer INC. | $109.28 | 2019-2025 | |
| Novo Nordisk INC | $104.13 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Astellas Pharma US INC | $70.89 | 2021-2024 | Veozah |
| Lilly USA, LLC | $68.57 | 2019-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.87 | 2019-2025 | Jardiance |
| Abbvie INC. | $48.60 | 2024-2025 | |
| Daiichi Sankyo INC. | $40.54 | 2019-2023 | Injectafer |
| Ultragenyx Pharmaceutical INC. | $33.33 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $30.05 | 2022-2023 | Breztri |
| Supernus Pharmaceuticals, INC. | $29.86 | 2022-2025 | Qelbree |
| Sanofi-Aventis U.S. LLC | $26.68 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $26.26 | 2022 | |
| Mylan Specialty L.P. | $25.34 | 2019-2020 | |
| Amarin Pharma, INC. | $24.87 | 2020-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $24.67 | 2021 | |
| Novartis Pharmaceuticals Corporation | $23.06 | 2022 | |
| The Binding Site INC. | $22.51 | 2023 | Freelite |
| Xeris Pharmaceuticals, INC. | $22.22 | 2025 | Gvoke Hypopen |
| Inspire Medical Systems, INC. | $19.31 | 2025 | Inspire |
| Ars Pharmaceuticals Operations, INC. | $19.12 | 2025 | Neffy |
| Exeltis, USA INC. | $18.34 | 2023 | Slynd |
| E.R. Squibb & Sons, L.L.C. | $17.46 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $16.30 | 2025 | |
| Abbott Laboratories | $16.22 | 2021 | |
| Nabriva Therapeutics, Plc | $16.11 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.07 | 2022 | |
| Medtronic Minimed, INC. | $16.04 | 2020 | |
| Corium, LLC | $16.00 | 2025 | Azstarys |
| Glaxosmithkline, LLC. | $14.59 | 2021 | |
| Merck Sharp & Dohme LLC | $14.42 | 2020 | |
| Dexcom, INC. | $13.95 | 2020 | |
| Adlon Therapeutics L.P. | $12.79 | 2020 | |
| Janssen Pharmaceuticals, INC | $12.25 | 2019 | |
| Gilead Sciences, INC. | $11.08 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathy Geraets listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.